(redirected from b-lactam)
Also found in: Dictionary.
Related to b-lactam: Cephalosporins


A class of broad-spectrum antibiotics that are structurally and pharmacologically related to the penicillins and cephalosporins.
Farlex Partner Medical Dictionary © Farlex 2012


(bā′tə-lăk′təm, bē′-)
1. A lactam composed of a four-membered ring, formed by intramolecular condensation of an amino acid in which the amino group is located at the beta position, or any compound containing this group.
2. A beta-lactam antibiotic.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


(bā'tă lak'tam)
Class of broad-spectrum antibiotics structurally and pharmacologically related to penicillins and cephalosporins.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
This kind of drug resistance is common in bacteria, which is dependent on b-lactam antibiotics rather than [beta]-lactamases (27).
The current study was planned to observe the AmpC b-lactamases which limits the therapeutic options for infections caused by gram-negative organisms and are usually resistant to all the b-lactam antibiotics.
In conclusion, the drug resistance is directly related to the clinical use time and range of b-lactam antibiotics.
This is a big problem in studying b-lactam resistance, as b-lactam resistance can increase due to inappropriate b-lactam use.
All cephelosporins and other b-lactam antibiotics were highly resistant (83-100%), except piperacillin/tazobactam with 42.6% resistance.
According to them, b-lactam resistance is widespread among Coliform bacteria due to vertical as well as horizontally acquired resistance factors.
In approximately 73% of the patients, the infecting strain of MRSA was resistant to prescribed antibiotics, yet in patients with skin or soft-tissue infections, treatment with inappropriate antimicrobials (usually B-lactam antibiotics) did not appear to correlate with differences in outcome (N.
PRIOR CATEGORY (add 000) SHARE YEAR TOTAL GENERICS $17,111,306 100% + 6% Codeine and combinations 874,089 5.1% +59% ACE inhibitors 790,580 4.6% +24% B-Lactam, increased activ.
This includes patients treated with a b-lactam drug during the prior 30 days, those who are immunosuppressed, and patients admitted to the intensive care unit.
Notable is the production of enzymes (beta [b]-lactamases) that cleave the b-lactam ring in the whole range of b-lactam antibiotics.
In particular, cephalosporin and carbapenem use correlates highly to subsequent infection with b-lactam and/or carbapenem resistant Acinetobacter spp as a consequence of collateral damage in various studies.12-15 Hence, the use of one antimicrobial agent can enhance resistance mechanisms of the organism to other antimicrobial agents.